Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA ADC in mCRPC
NCT01695044Phase 2Completed
- Sponsor
- Progenics Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of psma adc in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Progenics Pharmaceuticals. Started Sep 2012; status: completed.
02
Drugs
psma adc
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01695044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695044.